Work

Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas

Year: 2020

Type: article

Study design: Clinical Trial

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(20)31080-7

Authors: M.M. Gounder, T.M. Bauer, G.K. Schwartz, P. LoRusso, P. Kumar, K. Kato, B. Tao, Y. Hong, P. Patel, D. Hong

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Sarah Cannon, Tennessee Oncology, Columbia University Irving Medical Center, Yale Cancer Center, Smilow Cancer Hospital, Daiichi Sankyo (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3097389409

FWCI: 1.66

Cites:

Cited by: 18

Related to: 10